One of the Merck authors in the study was Alise Reicin, who helped spearhead the development of Vioxx and has been a key Merck witness.
FORBES: Hung Jury Leaves Merck Up In The Air
2.
In their letter, Peter Kim, Merck's research chief, and Alise Reicin, who headed up much of the development of Vioxx, defend their company's handling of the matter.